Last reviewed · How we verify
ALT005 Ophthalmic Prep Solution
ALT005 is an ophthalmic preparation designed to treat ocular surface disease through topical application to the eye.
ALT005 is an ophthalmic preparation designed to treat ocular surface disease through topical application to the eye. Used for Ocular surface disease (indication under investigation).
At a glance
| Generic name | ALT005 Ophthalmic Prep Solution |
|---|---|
| Sponsor | Altacor Ltd. |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
As an ophthalmic solution in Phase 3 development by Altacor Ltd., ALT005 is formulated for direct ocular delivery. Without disclosed mechanism details, the drug likely targets inflammatory or degenerative pathways affecting the anterior segment of the eye. The specific molecular target and therapeutic mechanism remain proprietary pending clinical disclosure.
Approved indications
- Ocular surface disease (indication under investigation)
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ALT005 Ophthalmic Prep Solution CI brief — competitive landscape report
- ALT005 Ophthalmic Prep Solution updates RSS · CI watch RSS
- Altacor Ltd. portfolio CI